The chief executive of Ireland-headquartered Allergan (NYSE: AGN) has vowed to limit price increases of its medicines and said it will not engage in ‘price gouging actions’ or ‘predatory pricing’.
In a blog post on the company’s website, Brent Saunders, condemned those ‘outliers’ who have imposed dramatic price increases on their products, accusing them of violating their social contract with patients.
He insisted that Allergan had made a formal commitment, as part of a 'social contract' to abide by ‘responsible pricing ideals’ and called on other companies in the industry to do the same.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze